La catena delle opzioni mostra i dati chiave delle opzioni azionarie di TRACON Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per TRACON Pharma..

TRACON Pharma (OTC:TCON) Azioni, Catena delle Opzioni

TRACON Pharma

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.

TRACON Pharmaceuticals Inc

<h4>Key Takeaways:</h4>
<ul>
<li>Alphamab Oncology could still succeed in developing its envafolimab drug outside of China after licensing some of the international rights to India&rsquo;s Glenmark</li>
<li>The R&amp;D woes could be related to staffing issues at Alphamab as the position of chief medical officer has been vacant for some time</li>
</ul>
By Molly Wen
The route to pharmaceutical profits must typically pass through global markets, and the path for Chinese drug developers is strewn with regulatory and clinical obstacles.
Cancer drug specialist&nbsp;Alphamab Oncology&nbsp;(OTC: ALMOF) has been finding the journey particularly arduous. In late May, one of its key products flunked a Phase Three clinical trial on pancreatic cancer patients. Then on July 1 came the&nbsp;<a href="https://www.clinicaltrialsarena.com/news/tracon-mulls-strategic-options-after-sarcoma-drug-fails-phase-ii-trial/">news</a>&nbsp;that the company&rsquo;s U.S. partner had scrapped an overseas trial of another Alphamab drug,citing a failure to achieve the targeted results.
Investors took fright at a second piece of unwelcome news in less than five weeks. The stock lost nearly a third of its value on the day of the latest announcement, going on to plunge 53% over three trading sessions.
Hopes have been high that the immune checkpoint drug envafolimab could treat a range of cancers through a simple injection. The drug is the first PD-L1 monoclonal antibody that can be injected via the skin rather than having to be fed intravenously into a vein.&nbsp; Since being approved for sale in China in 2021, envafolimab has been cleared for conditions such as advanced solid tumors, cholangiocarcinoma, soft tissue sarcoma and non-small cell lung cancer
But the firm&rsquo;s U.S. partner,&nbsp;Tracon Pharmaceuticals&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>), has pulled the plug on a trial in which the drug was used in a combined therapy to treat two types of cancer affecting the body&rsquo;s soft tissues, metastatic undifferentiated pleuromorphic sarcoma and myxfibrosarcoma. &nbsp;
The drug attracted a lot of interest because of the benefits of being injectable. In December 2019 Alphamab and co-developer&nbsp;3D Medicines&nbsp;(1244.HK) struck a deal with Tracon under which the U.S. firm would test and develop the drug in North America for treating soft tissue sarcoma.&nbsp; U.S. clinical trials were launched in 2020 but after four years the results showed an objective response rate of just 5% in 82 cases, not even half the 11% required for a marketing application.
The setback in the United States does not spell the end for the drug overseas. In January this year Alphamab licensed other overseas development rights to India&rsquo;s fourth-biggest pharmaceutical company, Glenmark.
For more than $700 million in upfront and milestone payments, Glenmark gained exclusive rights to develop and market the drug in multiple countries and regions. These include India, parts of the Asia Pacific, the Middle East, Africa, Russia, the Commonwealth of Independent States and Latin America. Under the deal, Glenmark has agreed to absorb the costs of developing and selling the drug in the targeted markets.
In China, the drug was developed and promoted in partnership with two other companies. As a result, Alphamab only owns a share of the Chinese drug rights. Under the arrangement, Alphamab took care of production and distribution while 3D Medicines handledclinical development, registration, marketing and sales.&nbsp;Simcere Pharmaceutical&nbsp;(2096.HK) also enjoys exclusive rights for commercial promotion of the drug, whose sales are divided among the partners. According to financial data from 3D Medicines, the drug generated 635 million yuan ($87.3 million) in sales in 2023, of which 196 million yuan went to Alphamab.
<h3>Successive Stumbles</h3>
The company&rsquo;s stock price has hovered around HK$2.5 over the past month, more than 70% below the 2019 IPO price of HK$10.2.
The stock took a beating on May 29 after another Alphamab drug, KN046, failed a Phase Three clinical trial. The drug is a bispecific antibody used against pancreatic cancer, which is a particularly malignant and fast-developing condition with few effective treatments. The abortive trial dampened hopes for a breakthrough drug, sending the share price plummeting nearly 45% on the day of the announcement.
A year earlier the company had announced the failure of another trial in which KN046 was used with chemotherapy for patients with advanced squamous non-small cell lung cancer. The drug still has more than 10 clinical trials underway in China and elsewhere, covering multiple conditions such as thymus cancer, liver cancer and esophageal squamous cell cancer. The company could be further hit if any of those trials progress slowly or produce disappointing results.
The setbacks come after a period of staffing flux for Alphamab. The company announced in March 2021 that Johannes Nippgen, former head of Merck&rsquo;s R&amp;D center in China, had been appointed chief medical officer to lead the global development of its novel drug pipelines. Just a year later, Nippgen joined another drug company, Ionova Life Science, leaving the CMO role at Alphamab vacant.
At present, the company lacks any actively advancing pipelines. Its only drug on the market, envafolimab, is generating modest sales, while the hopes pinned on KN046 have dwindled and no other product launch is on the horizon. Nonetheless, the stock is trading at a price-to-sales (P/S) ratio of 10 times, a decent premium over the two times for 3D Medicines.
Investors will need to watch how Alphamab manages to pay its way in the future, in the absence of a powerful revenue engine.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Penny Stocks

TCON

Clinical Trials Come Up Short Again For Alphamab Oncology

HC Wainwright &amp; Co. analyst Edward White downgrades TRACON Pharma (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCON#OTC">TCON</a>) from Buy to Neutral.

News

Downgrades

Analyst Ratings

HC Wainwright & Co. Downgrades TRACON Pharma to Neutral

<h3>Gainers</h3>
<ul>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares moved upwards by 17.95% to $0.6. The company's market cap stands at $7.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock declined by 63.5% to $1.2 during Monday's pre-market session. The market value of their outstanding shares is at $85.1 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares decreased by 27.48% to $0.37. The market value of their outstanding shares is at $1.0 million. </li>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) shares declined by 16.98% to $3.18. The market value of their outstanding shares is at $77.4 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 12.72% to $0.67. The market value of their outstanding shares is at $2.7 million. </li>
<li>BIMI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) stock fell 12.12% to $1.85. The company's market cap stands at $25.8 million. </li>
<li>Holdco Nuvo Group DG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) shares fell 10.19% to $1.5. The company's market cap stands at $49.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APVO

BIMI

BJDX

ELUT

NDRA

NUVO

OVID

SCNI

THAR

VERO

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) rose sharply in today's pre-market trading after the company posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/24/06/39301030/broadcom-q2-earnings-revenue-eps-beat-driven-by-strong-ai-demand-guidance-raise-stock-split-and-mor">results for its second quarter</a>.
The company declared a quarterly dividend of $5.25 per share and also announced a 10-for-1 forward stock split. Broadcom boosted its fiscal year 2024 revenue guidance to approximately $51 billion, up from approximately $50 billion.
Broadcom shares surged 13.5% to $1,698.20 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) rose 79.3% to $1.17 in pre-market trading.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares rose 36.9% to $0.8350 in pre-market trading after surging 5% on Wednesday.</li>
<li>Grupo Supervielle S.A.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) gained 22.7% to $8.05 in pre-market trading after rising 6% on Wednesday.</li>
<li>Molecular Partners AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) gained 22.1% to $7.08 in pre-market trading after gaining 16% on Wednesday. Molecular Partners recently announced the debut of their lead Raido-DARPin therapy candidate MP0712, targeting DLL3.</li>
<li>Longeveron Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares climbed 16% to $2.10 in pre-market trading. Longeveron shares jumped over 120% on Wednesday following the circulation of a Zacks Small Cap Research note valuing the stock at $15.10 per share.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares gained 15.3% to $0.6025 in pre-market trading after falling 5% on Wednesday.</li>
<li>CaliberCos Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) rose 11.5% to $1.07 in pre-market trading.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares rose 10% to $1.10 in pre-market trading after falling 7% on Wednesday. TRACON Pharmaceuticals recently announced publication of Phase 2 clinical data for TRC102 in patients with glioblastoma in clinical cancer research.</li>
<li>Vista Energy, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIST#NYSE">VIST</a>) shares rose 7.1% to $47.18 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares declined 58.2% to $0.2174 in pre-market trading.</li>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) shares declined 26% to $1.14 in pre-market trading. DayDayCook shares jumped 198% on Wednesday after the company announced it has acquired Omsom.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares fell 19.2% to $0.6250 in pre-market trading after surging around 19% on Wednesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares fell 19% to $0.4358 in pre-market trading after gaining 10% on Wednesday.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) shares dipped 18.3% to $0.3225 in pre-market trading.</li>
<li>J.Jill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) fell 15.7% to $33.36 in pre-market trading. J.Jill priced its public offering of 2 million common stock at $31 per share.</li>
<li>Cara Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares fell 11.7% to $0.60 in pre-market trading. Cara Therapeutics discontinued clinical program for oral difelikefalin in notalgia paresthetica after KOURAGE-1 study showed no meaningful clinical benefit at any dose compared to placebo.</li>
<li>Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) shares fell 10.6% to $45.03 in pre-market trading after the company posted downbeat results for its first quarter on Wednesday.</li>
<li>EpicQuest Education Group International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) shares declined 10% to $0.8292 in pre-market trading.</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares fell 8.3% to $0.78 in pre-market trading after the company announced it will effect a reverse stock split.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/06/39305484/s-p-500-tops-5-400-as-federal-reserve-holds-rates-steady-inflation-eases#google_vignette">S&amp;P 500 Tops 5,400 As Federal Reserve Holds Rates Steady, Inflation Eases</a>

Pre-Market Outlook

Markets

Trading Ideas

AEMD

AVGO

CARA

EEIQ

IONM

JILL

LGVN

MOLN

PLAY

PRFX

PTPI

SPCE

SUPV

VIST

Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Holdco Nuvo Group DG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) shares increased by 21.5% to $1.92 during Wednesday's after-market session. The company's market cap stands at $63.8 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares moved upwards by 8.69% to $2.25. The company's market cap stands at $6.1 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 7.4% to $1.45. The market value of their outstanding shares is at $34.5 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock increased by 5.92% to $0.29. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) stock increased by 5.53% to $0.57. The market value of their outstanding shares is at $28.3 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 5.05% to $1.87. The company's market cap stands at $1.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares fell 38.4% to $0.32 during Wednesday's after-market session. The company's market cap stands at $2.8 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) stock declined by 10.26% to $1.05. The company's market cap stands at $25.1 million. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares declined by 5.58% to $4.4. The company's market cap stands at $165.3 million. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) shares decreased by 5.01% to $0.94. The company's market cap stands at $4.5 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares fell 5.0% to $0.95. The market value of their outstanding shares is at $2.5 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) shares declined by 4.93% to $5.21. The market value of their outstanding shares is at $209.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPHI

ENTO

HOTH

NUTX

ONMD

RNXT

RZLT

VIGL

12 Health Care Stocks Moving In Wednesday's After-Market Session

Shares of Streamline Health Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) fell sharply during Wednesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/STRM/earnings">first-quarter EPS results</a>.
Streamline Health reported quarterly losses of 5 cents per share which missed the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $4.33 million which beat the analyst consensus estimate of $4.31 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Streamline Health Solutions shares dipped 23.3% to $0.4902 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) surged 101% to $1.04. DDC Enterprise said it has acquired Omsom.</li>
<li>Golden Heaven Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares climbed 59.7% to $0.2866.</li>
<li>Beamr Imaging Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMR#NASDAQ">BMR</a>) gained 39.3% to $6.08 after the company announced that its Beamr Cloud solution has achieved Powered by Expertise and is now available in the Oracle Cloud Marketplace.</li>
<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) climbed 27% to $36.56 after the company announced initial AOC 1020 data from the Phase 1/2 FORTITUDE trial demonstrating reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) jumped 26.6% to $3.99.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares rose 24.3% to $0.7602 after surging 16% on Tuesday.</li>
<li>MediaCo Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) rose 20.5% to $1.92. BestGrowthStocks.com issued comprehensive evaluation of MediaCo Holding Inc.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) gained 18.6% to $7.41.</li>
<li>Casey&#8217;s General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) rose 16.5% to $380.41 after the company reported better-than-expected quarterly financial results. Also, the company increased its quarterly dividend.</li>
<li>Hudson Pacific Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) surged 15.8% to $5.41.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) jumped 15.6% to $6.15.</li>
<li>Rentokil Initial plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>) gained 15.5% to $31.10 following a report suggesting Trian has amassed a stake in the company.</li>
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) rose 15.5% to $4.0650 after the company and Ultragenyx Pharmaceutical announced 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study.</li>
<li>Fenbo Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) climbed 15.4% to $14.88.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) gained 13.8% to $38.45. Brittain Resorts &amp; Hotels selected Affirm as exclusive pay over time partner to bring hotel guests a more flexible way to book accommodations.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 13% to $3.92.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) gained 12.8% to $47.12. Zillow Group Director Jay C Hoag acquired a total of 2,338,036 shares at an average price of $42.76.</li>
<li>Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) gained 10.7% to $137.08 after the company reported fourth-quarter financial results. Oracle posted weaker-than-expected earnings for its fiscal fourth quarter. The company also announced a partnership with Alphabet Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google Cloud.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) climbed 10.3% to $26.83.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) rose 9.9% to $13.58.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) gained 3.7% to $214.73.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares dipped 46.2% to $1.1469. Tonix Pharmaceuticals priced its $4 million public offering of 3,753,558 shares of common stock at $1.065 per share.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) fell 35.7% to $8.69.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) fell 31% to $0.3780 after the Nasdaq denied the company's request for continued listing and the stock will be suspended at the opening of business on June 17.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) tumbled 31% to $0.1870. The company recently announced that it may now offer and sell shares of common stock offering price of up to $8.4 million from time to time through or to Wainwright.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) fell 24.1% to $0.82.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) shares fell 20.1% to $0.8168 after jumping around 17% on Tuesday. KWESST Micro Systems was recently awarded a sub-contract worth up to C$48 million by Thales Canada for software development services.</li>
<li>Vera Bradley, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) declined 16.8% to $6.44 following a first-quarter revenue miss and weak FY25 guidance.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) fell 15.8% to $1.6150.</li>
<li>Calidi Biotherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) shares fell 14.1% to $4.1350 after jumping around 32% on Tuesday. Calidi Biotherapeutics recently announced collaboration with SIGA Technologies to advance Calidi&#8217;s RTNova virotherapy for lung cancer and metastatic solid tumors.</li>
<li>ReTo Eco-Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RETO#NASDAQ">RETO</a>) declined 12.4% to $2.19.</li>
<li>PetMed Express, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) shares fell 12.1% to $4.1350 following mixed fourth-quarter results. The company said results were negatively impacted by a challenging macro environment and industry dynamics.</li>
<li>SmartKem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>) declined 11.7% to $6.10.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) dipped 9.9% to $0.4036.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) fell 8.2% to $15.84</li>
<li>Oblong, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) fell 8.1% to $0.1847 after declining 5% on Tuesday. Obglong recently signed a non-binding letter of intent to acquire Dwellwell Analytics.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/top-stories/24/06/39290971/jim-cramer-likes-this-energy-stock-with-4-yield-recommends-buying-draftkings">Jim Cramer Likes This Energy Stock With 4% Yield, Recommends Buying DraftKings</a>

Intraday Update

AAPL

AFRM

AVGR

CASY

CLDI

DRCT

ENVX

FEBO

GDHG

GOOG

GOOGL

KITT

MDIA

MREO

NOVA

OBLG

ORCL

PETS

RDFN

RETO

SIFY

SMTK

STRM

THMO

TNXP

UPST

WLGS

WULF

Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. </li>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 20.94% to $1.42. The market value of their outstanding shares is at $26.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares fell 31.4% to $0.38 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 25.92% to $0.8. The company's market cap stands at $2.1 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 21.86% to $0.5. The market value of their outstanding shares is at $31.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock fell 21.76% to $2.59. The market value of their outstanding shares is at $30.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 16.67% to $0.23. The market value of their outstanding shares is at $14.4 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 16.16% to $1.61. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

CYCN

NNVC

TBIO

VTVT

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.84% to 39,072.22 while the NASDAQ rose 0.87% to 17,494.72. The S&amp;P 500 also rose, gaining, 0.84% to 5,420.33.
Check This Out: <a href="https://www.benzinga.com/news/24/06/39289458/general-motors-toll-brothers-and-2-other-stocks-insiders-are-selling">General Motors, Toll Brothers And 2 Other Stocks Insiders Are Selling</a>
Leading and Lagging Sectors Real estate shares jumped by 2.1% on Wednesday.
In trading on Wednesday, consumer staples shares rose by just 0.1%.
Top Headline
The annual CPI inflation rate fell from 3.4% to 3.3% in May, below than the median economist projection of 3.4%. According to Econoday, the economist consensus ranged from 3.3% to 3.5%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Golden Heaven Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares shot up 51% to $0.2700.</li>
<li>Shares of Beamr Imaging Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMR#NASDAQ">BMR</a>) got a boost, surging 40% to $6.19 after the company announced that its Beamr Cloud solution has achieved Powered by Expertise and is now available in the Oracle Cloud Marketplace.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares were also up, gaining 29% to $0.78 after surging 16% on Tuesday.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares dropped 49% to $1.09. Tonix Pharmaceuticals priced its $4 million public offering of 3,753,558 shares of common stock at $1.065 per share.</li>
<li>Shares of ThermoGenesis Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) were down 39% to $0.3290 after the Nasdaq denied the company's request for continued listing and the stock will be suspended at the opening of business on June 17.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) was down, falling 28% to $0.78.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/06/39288935/uber-to-rally-around-38-here-are-10-top-analyst-forecasts-for-wednesday">Uber To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Wednesday</a> 
Commodities In commodity news, oil traded up 1.1% to $78.79 while gold traded up 0.2% at $2,330.10.
Silver traded up 1.9% to $29.495 on Wednesday, while copper rose 0.1% to $4.5150.
Euro zone
European shares were lower today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX gained 0.6% and France's CAC 40 rose 0.5%. Spain's IBEX 35 Index rose 0.4%, while London's FTSE 100 rose 0.7%.
German consumer price inflation increased to 2.4% in May from a three-year low of 2.2% in the prior month.
The UK&#8217;s trade deficit increased to around two-year high of £6.75 billion in April, while British economy stalled during April following a 0.4% expansion in March. Industrial production in the UK fell 0.9% month-over-month for April.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.66%, Hong Kong's Hang Seng Index falling 1.31%, China's Shanghai Composite Index gaining 0.31% and India's S&amp;P BSE Sensex gaining 0.20%.
Total passenger vehicle sales in India rose 4.3% year-over-year to 300,795 in May following a 1.2% gain in the prior month. Producer prices in Japan rose 2.4% year-over-year in May compared to a revised 1.1% increase in April.
Chinese annual inflation rate came in at 0.3% in May versus market estimates of 0.4%, while producer prices fell by 1.4% year-over-year in May.
Economics
<ul>
<li>The annual CPI inflation rate fell from 3.4% to 3.3% in May, below than the median economist projection of 3.4%. According to Econoday, the economist consensus ranged from 3.3% to 3.5%.</li>
<li>On a monthly basis, the overall CPI inflation stalled, decelerating from the prior 0.3% growth and coming in below expectations of 0.1%.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39288706/top-2-utilities-stocks-that-may-rocket-higher-in-june">Top 2 Utilities Stocks That May Rocket Higher In June</a>

Eurozone

Commodities

Dow Surges Over 300 Points; US Inflation Rate Slows In May

<h3>Gainers</h3>
<ul>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. </li>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. </li>
<li>Oramed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORMP#NASDAQ">ORMP</a>) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock rose 12.72% to $3.1. The market value of their outstanding shares is at $3.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares decreased by 40.5% to $0.33 during Wednesday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 11.86% to $0.24. The market value of their outstanding shares is at $15.2 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares decreased by 10.94% to $0.57. The market value of their outstanding shares is at $35.4 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares decreased by 8.28% to $0.8. The company's market cap stands at $132.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 8.11% to $1.7. The market value of their outstanding shares is at $2.4 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) stock fell 7.91% to $0.28. The market value of their outstanding shares is at $53.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

CYCC

ORMP

TVGN

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy
Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment

Biotech

General

TRACON Pharmaceuticals Announces Publication Of Phase 2 Clinical Data For TRC102 In Patients With Glioblastoma In Clinical Cancer Research; Study Highlights Activity Of TRC102 Combined With Temodar Chemotherapy In Recurrent Glioblastoma

<h3>Gainers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock rose 17.0% to $0.17 during Friday's after-market session. The company's market cap stands at $5.0 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock increased by 12.79% to $3.35. The company's market cap stands at $1.9 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 9.17% to $0.45. The company's market cap stands at $2.1 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock rose 8.77% to $1.24. The market value of their outstanding shares is at $3.3 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock increased by 6.36% to $1.17. The market value of their outstanding shares is at $7.7 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares rose 5.64% to $0.28. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 7.8% to $0.54 during Friday's after-market session. The company's market cap stands at $2.7 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares decreased by 7.68% to $0.52. The company's market cap stands at $9.7 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares declined by 6.41% to $0.78. The company's market cap stands at $128.7 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) shares fell 5.95% to $5.38. The market value of their outstanding shares is at $215.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 5.92% to $0.26. The company's market cap stands at $12.0 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares decreased by 5.01% to $0.95. The market value of their outstanding shares is at $96.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

RNAZ

SBFM

SLRX

SNTI

TLSA

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares increased by 57.2% to $7.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $665.3 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares moved upwards by 36.08% to $0.48. The company's market cap stands at $11.8 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) stock moved upwards by 32.45% to $0.8. The market value of their outstanding shares is at $5.6 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) stock moved upwards by 15.96% to $7.12. The market value of their outstanding shares is at $262.7 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares rose 15.74% to $1.47. The market value of their outstanding shares is at $3.9 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock increased by 15.41% to $3.07. The company's market cap stands at $18.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares declined by 24.1% to $2.45 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares declined by 9.3% to $0.49. The market value of their outstanding shares is at $4.2 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 8.88% to $0.35. The market value of their outstanding shares is at $5.4 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) shares decreased by 8.17% to $1.8. The company's market cap stands at $4.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 7.98% to $1.27. The market value of their outstanding shares is at $12.8 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 7.84% to $0.8. The company's market cap stands at $17.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANNX

BPTH

FRES

KDLY

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

MYNZ

NIVF

STSS

XCUR

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Shares of GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) rose sharply in <a href="https://www.benzinga.com/markets/equities/24/06/39130795/gamestop-nearly-doubles-amc-soars-30-premarket-whats-setting-meme-stocks-on-fire-again">today's pre-market trading</a> .
The rally in the stock came on the back of Keith Gill, also known as "Roaring Kitty," disclosing a substantial position in GameStop on the r/Superstonk Reddit forum.
GameStop shares jumped 69.1% to $39.12 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MingZhu Logistics Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) rose 69.5% to $0.5931 in today's pre-market trading after the company reported an agreement to acquire Oxylus Global.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares gained 31.3% to $1.68 in pre-market trading. On May 14, TRACON Pharmaceuticals reported worse-than-expected first-quarter EPS results.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) gained 25.6% to $5.44 in pre-market trading. The resumption of the meme rally came on the back of Keith Gill, also known as "Roaring Kitty," disclosing a substantial position in GameStop on the r/Superstonk Reddit forum.</li>
<li>Earlyworks Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) gained 25% to $2.65 in pre-market trading. Earlyworks and ZenmuTech announced a collaboration for a more secure digital society through secret splitting and blockchain.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 24% to $0.1239 in pre-market trading after dipping 12% on Friday.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) gained 18.6% to $33.79 in pre-market trading.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares gained 17.3% to $0.6850 in pre-market trading after gaining over 3% on Friday.  </li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) rose 17.2% to $1.70 in pre-market trading after gaining 5% on Friday.</li>
<li>Molecular Partners AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares climbed 14.4% to $4.30 in pre-market trading. Molecular Partners presented data from completed Phase 1 trial of MP0317 monotherapy in advanced solid tumors at ASCO 2024.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Portage Biotech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares declined 25.2% to $0.3581 in pre-market trading after gaining over 91% on Friday.</li>
<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares declined 23.5% to $0.3291 in pre-market trading.</li>
<li>Abits Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares dipped 14% to $0.58 in pre-market trading following a 4% decline on Friday.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) shares fell 12.5% to $0.7869 in pre-market trading after jumping around 32% on Friday.</li>
<li>Global Gas Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGAS#NASDAQ">HGAS</a>) shares fell 12% to $1.10 in pre-market trading after gaining around 9% on Friday.</li>
<li>Digital Health Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAC#NASDAQ">DHAC</a>) shares fell 11.4% to $15.03 in pre-market trading after gaining 13% on Friday.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares fell 11.2% to $4.83 in pre-market trading after jumping over 110% on Friday.</li>
<li>EpicQuest Education Group Internatnl Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) shares fell 10.4% to $0.75 in pre-market trading after gaining over 7% on Friday.</li>
<li>UTime Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) fell 10.4% to $0.43 in pre-market trading after gaining 10% on Friday.</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) shares declined 9.2% to $40.66 in pre-market trading. GSK said it disagrees with ruling by Delaware State Court that contradicts Federal Court&#8217;s Multidistrict litigation ruling, which dismissed all cases alleging five cancer types, in Dec. 2022. The company said it will immediately seek an appeal.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/06/39130380/investor-optimism-improves-us-stocks-record-gains-for-may">Investor Optimism Improves; US Stocks Record Gains For May</a>

ABTS

BNAI

CRKN

DHAC

ELWS

FFIE

HGAS

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

ISPC

PRTG

YGMZ

Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares moved upwards by 22.8% to $12.87. The market value of their outstanding shares is at $234.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 20.57% to $1.0. The market value of their outstanding shares is at $50.7 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 67.0% to $0.76 during Wednesday's regular session. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 50.35% to $0.42. The company's market cap stands at $1.1 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock decreased by 37.84% to $3.27. The company's market cap stands at $2.1 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares declined by 33.12% to $0.88. The company's market cap stands at $33.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.91% to $0.73. The market value of their outstanding shares is at $54.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares declined by 18.27% to $1.61. The market value of their outstanding shares is at $3.6 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

BOLT

EYEN

NTRB

OPRX

SINT

TTOO

VRPX

YTEN

WIIM

TRACON Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 EPS results.

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock increased by 18.92% to $9.67. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) stock increased by 17.24% to $0.66. The market value of their outstanding shares is at $426.5 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) shares moved upwards by 15.45% to $3.66. The company's market cap stands at $49.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) shares increased by 15.11% to $0.47. The market value of their outstanding shares is at $2.2 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock rose 14.4% to $0.44. The market value of their outstanding shares is at $8.4 million. The company's, Q1 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 60.5% to $0.91 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock decreased by 29.56% to $0.93. The market value of their outstanding shares is at $35.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock decreased by 19.29% to $1.59. The market value of their outstanding shares is at $3.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock fell 18.48% to $2.03. The market value of their outstanding shares is at $6.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 17.78% to $0.7. The market value of their outstanding shares is at $1.8 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock declined by 13.45% to $0.29. The market value of their outstanding shares is at $42.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARQT

CASI

DYNT

MPLN

RBOT

VIRI

VVOS

TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) reported quarterly losses of $(1.33) per share which missed the analyst consensus estimate of $(1.19) by 11.76 percent. This is a 269.44 percent decrease over losses of $(0.36) per share from the same period last year. The company reported $100.00 thousand in sales this quarter.

Earnings

Earnings Misses

TRACON Pharma Q1 EPS $(1.33) Misses $(1.19) Estimate, Sales $100.00K

<h3>Gainers</h3>
<ul>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares increased by 27.0% to $0.51 during Wednesday's after-market session. The company's market cap stands at $9.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock increased by 11.97% to $0.43. The company's market cap stands at $4.4 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock rose 10.32% to $0.04. The market value of their outstanding shares is at $5.0 million. </li>
<li>Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIO#NASDAQ">FBIO</a>) stock moved upwards by 6.21% to $1.88. The market value of their outstanding shares is at $36.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock increased by 5.92% to $1.43. The company's market cap stands at $4.5 million. </li>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) shares moved upwards by 5.51% to $0.17. The company's market cap stands at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 16.6% to $1.91 during Wednesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock fell 14.05% to $1.04. The market value of their outstanding shares is at $42.1 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares fell 8.92% to $0.62. The company's market cap stands at $1.4 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares declined by 7.85% to $0.47. The market value of their outstanding shares is at $4.9 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares declined by 7.7% to $1.68. The market value of their outstanding shares is at $4.3 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) shares declined by 6.7% to $2.65. The company's market cap stands at $163.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFIB

DHAI

FBIO

INVO

MBIO

PROK

SNGX

TCBP

TRVN

VRAX

Shares of The Travelers Companies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/trv#NYSE">TRV</a>) fell sharply during Wednesday&rsquo;s session following first-quarter earnings.
Travelers reported a mixed first quarter, with earnings lagging analyst&#39; expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier.
Travelers shares dipped 8.1% to $205.03 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>INVO Bioscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/invo#NASDAQ">INVO</a>) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goal of reaching break-even or profitability within its current operations in 2024.</li>
<li>Edible Garden AG Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edbl#NASDAQ">EDBL</a>) gained 112% to $9.73 after the company reported preliminary first quarter FY24 results.</li>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) jumped 53% to $0.0350.</li>
<li>VIA optronics AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/viao#NYSE">VIAO</a>) shares gained 50.4% to $0.3924 after dipping over 15% on Tuesday.</li>
<li>AERWINS Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/awin#NASDAQ">AWIN</a>) jumped 42.2% to $4.70.</li>
<li>The Children&#39;s Place, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plce#NASDAQ">PLCE</a>) climbed 35.5% to $9.64 after the company announced it entered into a new financing agreement with Mithaq Capital.</li>
<li>Vanda Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vnda#NASDAQ">VNDA</a>) gained 32% to $5.38 after the company announced that it submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals and confirmed that its most recent proposal to acquire Vanda remains open for Vanda and its Board of Directors to consider.</li>
<li>EZGO Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezgo#NASDAQ">EZGO</a>) gained 28% to $2.20. EZGO entered into a strategic cooperation framework agreement with Woteam to jointly explore the Southeast Asian Market.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) shares rose 25% to $4.89 after the company announced 24% ARR growth in 2023.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) rose 19.6% to $2.0461.</li>
<li>WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) gained 19% to $7.32 on continued upward momentum after the company announced a 5-year WiSA E licensing agreement with an HDTV/PTV brand.</li>
<li>Viracta Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/virx#NASDAQ">VIRX</a>) climbed 19% to $0.8501. Oppenheimer analyst Hartaj Singh maintained Viracta Therapeutics with an Outperform and maintained a $13 price target.</li>
<li>Spectaire Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spec#NASDAQ">SPEC</a>) rose 17.5% to $0.94 after the company announced that it signed a distribution partnership agreement with a Fortune 1000 Energy Company.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rani#NASDAQ">RANI</a>) jumped 14.4% to $7.86.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgem#NASDAQ">CGEM</a>) gained 14% to $19.75. HC Wainwright &amp; Co. analyst Edward White maintained Cullinan Oncology with a Buy and lowered the price target from $34 to $29.</li>
<li>United Airlines Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ual#NASDAQ">UAL</a>) rose 11.2% to $46.12 after the company reported better-than-expected first-quarter financial results.</li>
<li>Chromocell Therapeutics Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chro#NYSE">CHRO</a>) gained 11.8% to $2.0356 after falling around 7% on Tuesday.</li>
<li>ALX Oncology Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alxo#NASDAQ">ALXO</a>) rose 10.4% to $16.01.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) gained 7.5% to $2.9250, bouncing back from the selling pressure the stock has faced in recent week.</li>
<li>Interactive Brokers Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibkr#NASDAQ">IBKR</a>) rose 5.2% to $112.93 following upbeat quarterly earnings.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>ICZOOM Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/izm#NASDAQ">IZM</a>) shares dipped 87.8% to $6.19.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) fell 47% to $3.5879.</li>
<li>Trio Petroleum Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tpet#NYSE">TPET</a>) fell 35.8% to $0.3144 after dipping over 22% on Tuesday.</li>
<li>Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) dipped 31% to $2.43 after the company announced the exercise of warrants for $6.2 million in gross proceeds.</li>
<li>iSun, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isun#NASDAQ">ISUN</a>) declined 27% to $0.1556.</li>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtc#NASDAQ">SXTC</a>) fell 25.7% to $1.2001. China SXT Pharmaceuticals shares jumped 38% on Tuesday following a post on X from trader Zack Morris mentioning the stock.</li>
<li>Portage Biotech Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prtg#NASDAQ">PRTG</a>) fell 25.3% to $0.21. The company recently announced that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.</li>
<li>Trilogy Metals Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmq#NYSE">TMQ</a>) shares fell 23.2% to $0.3865.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) dipped 22.6% to $1.44.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) fell 22% to $33.83 after gaining around 18% on Tuesday.</li>
<li>Finch Therapeutics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fnch#NASDAQ">FNCH</a>) dipped 21.9% to $2.42.</li>
<li>Sage Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sage#NASDAQ">SAGE</a>) shares fell 20.8% to $12.37. The company announced topline results from Phase 2 PRECEDENT study of dalzanemdor for the treatment of people with mild cognitive impairment in Parkinson&#39;s Disease.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) fell 20.3% to $0.3666 after the company reported worse-than-expected quarterly financial results.</li>
<li>SolarMax Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) dipped 20% to $9.72 following fiscal year 2023 results.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dfli#NASDAQ">DFLI</a>) declined 15.8% to $0.5199. Dragonfly Energy shares jumped over 36% on Tuesday after the company reported better-than-expected fourth-quarter EPS results.</li>
<li>Montrose Environmental Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/meg#NYSE">MEG</a>) fell 13.3% to $36.37 after announcing a public offering of 3 million shares.</li>
<li>Dynatronics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dynt#NASDAQ">DYNT</a>) fell 12.2% to $0.50 after gaining around 48% on Tuesday.</li>
<li>VinFast Auto Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vfs#NASDAQ">VFS</a>) fell 12% to $2.70 following first-quarter earnings.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>) declined 9.3% to $2.4950.</li>
<li>SNDL Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sndl#NASDAQ">SNDL</a>) fell 9.3% to $1.7950.</li>
<li>Arm Holdings plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arm#NASDAQ">ARM</a>) fell 9.3% to $110.65.</li>
<li>J B Hunt Transport Services Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jbht#NASDAQ">JBHT</a>) shares fell 9.2% to $166.25 after the company missed first-quarter revenue and EPS estimates.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) dipped 8.8% to $1,143.81. MicroStrategy is expected to report its financial results for the first quarter of 2024 after the closing bell on April 29, 2024.</li>
<li>Forward Air Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwrd#NASDAQ">FWRD</a>) fell 8.3% to $23.13.</li>
<li>Autodesk, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adsk#NASDAQ">ADSK</a>) fell 7.1% to $211.97 after the company announced that it will not file its Annual Report on Form 10-K for the year ended Jan. 31, 2024 within the 15-day extension period. The company provided an update on the previously reported internal investigation that is currently being conducted by the Audit Committee.</li>
<li>ASML Holding N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asml#NASDAQ">ASML</a>) shares declined 7.2% to $907.11 after the company reported worse-than-expected first-quarter results and issued second-quarter guidance.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38293462/discover-financial-gears-up-for-q1-print-these-most-accurate-analysts-revise-forecasts-ahead-of-ear"> Discover Financial Gears Up For Q1 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Small Cap

ADPT

ADSK

ALXO

ASML

AWIN

CGEM

CHRO

CXAI

DFLI

DXYZ

EDBL

EZGO

FNCH

FWRD

HUBC

IBKR

ISUN

JBHT

MSTR

OTRK

PLCE

RANI

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Comments

TRACON Pharma

TRACON Pharma (TCON) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO